{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T22:30:45Z","timestamp":1779402645290,"version":"3.53.1"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.bmc.2021.116000","type":"journal-article","created":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T04:56:57Z","timestamp":1610168217000},"page":"116000","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Design, synthesis, and antiviral activity of a series of CD4-mimetic small-molecule HIV-1 entry inhibitors"],"prefix":"10.1016","volume":"32","author":[{"given":"Francesca","family":"Curreli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6184-7016","authenticated-orcid":false,"given":"Shahad","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia M.","family":"Benedict Victor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ildar R.","family":"Iusupov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4071-0344","authenticated-orcid":false,"given":"Evgeny A.","family":"Spiridonov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry S.","family":"Belov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9815-9866","authenticated-orcid":false,"given":"Andrea","family":"Altieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander V.","family":"Kurkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asim K.","family":"Debnath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2021.116000_b0005","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.tim.2011.02.001","article-title":"HIV envelope: challenges and opportunities for development of entry inhibitors","volume":"19","author":"Caffrey","year":"2011","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.bmc.2021.116000_b0010","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3390\/v4020309","article-title":"Novel approaches to inhibit HIV entry","volume":"4","author":"Didigu","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.bmc.2021.116000_b0015","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3390\/v5010127","article-title":"Approaches for identification of HIV-1 entry inhibitors targeting gp41 pocket","volume":"5","author":"Yu","year":"2013","journal-title":"Viruses"},{"key":"10.1016\/j.bmc.2021.116000_b0020","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.2174\/1568026615666150901114527","article-title":"Development of small-molecule HIV entry inhibitors specifically targeting gp120 or gp41","volume":"16","author":"Lu","year":"2016","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.bmc.2021.116000_b0025","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1345\/aph.1D143","article-title":"Enfuvirtide: a novel agent for the treatment of HIV-1 infection","volume":"37","author":"Duffalo","year":"2003","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.bmc.2021.116000_b0030","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1592\/phco.24.2.198.33141","article-title":"Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection","volume":"24","author":"Hardy","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.bmc.2021.116000_b0035","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1128\/AAC.49.11.4721-4732.2005","article-title":"Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity","volume":"49","author":"Dorr","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2021.116000_b0040","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1592\/phco.29.3.295","article-title":"Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1","volume":"29","author":"Hunt","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.bmc.2021.116000_b0045","first-page":"669","article-title":"Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS","volume":"8","author":"Meanwell","year":"2007","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.bmc.2021.116000_b0050","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.virol.2005.06.008","article-title":"Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4","volume":"339","author":"Zhao","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.bmc.2021.116000_b0055","doi-asserted-by":"crossref","first-page":"5036","DOI":"10.1073\/pnas.0307953101","article-title":"Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins","volume":"101","author":"Si","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bmc.2021.116000_b0060","doi-asserted-by":"crossref","first-page":"6909","DOI":"10.1021\/acs.jmedchem.5b00709","article-title":"Structure-based design of a small molecule CD4-antagonist with broad spectrum anti-HIV-1 activity","volume":"58","author":"Curreli","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2021.116000_b0065","doi-asserted-by":"crossref","first-page":"5478","DOI":"10.1128\/AAC.03339-14","article-title":"Binding mode characterization of NBD series CD4-mimetic HIV-1 entry inhibitors by X-ray structure and resistance study","volume":"58","author":"Curreli","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2021.116000_b0070","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1021\/jm3002247","article-title":"Design, synthesis and antiviral activity of entry inhibitors that target the CD4-binding site of HIV-1","volume":"55","author":"Curreli","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2021.116000_b0075","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1016\/j.bmc.2016.09.057","article-title":"Design, synthesis and evaluation of small molecule CD4-mimics as entry inhibitors possessing broad spectrum anti-HIV-1 activity","volume":"24","author":"Curreli","year":"2016","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2021.116000_b0080","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1021\/ar4002735","article-title":"Structure-based design, synthesis and validation of CD4-mimetic small molecule inhibitors of HIV-1 entry: conversion of a viral entry agonist to an antagonist","volume":"47","author":"Courter","year":"2014","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.bmc.2021.116000_b0085","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.bmc.2010.11.049","article-title":"Design, synthesis and biological evaluation of small molecule inhibitors of CD4-gp120 binding based on virtual screening","volume":"19","author":"Lalonde","year":"2011","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2021.116000_b0090","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1021\/ml300407y","article-title":"Structure-based design and synthesis of an HIV-1 entry inhibitor exploiting X-ray and thermodynamic characterization","volume":"4","author":"Lalonde","year":"2013","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2021.116000_b0095","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1021\/acsmedchemlett.5b00471","article-title":"Small-molecule CD4-mimics: structure-based optimization of HIV-1 entry inhibition","volume":"7","author":"Melillo","year":"2016","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2021.116000_b0100","doi-asserted-by":"crossref","first-page":"7884","DOI":"10.1016\/j.bmc.2013.10.005","article-title":"A CD4 mimic as an HIV entry inhibitor: Pharmacokinetics","volume":"21","author":"Hashimoto","year":"2013","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2021.116000_b0105","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1016\/j.bmc.2013.02.041","article-title":"CD4 mimics as HIV entry inhibitors: lead optimization studies of the aromatic substituents","volume":"21","author":"Narumi","year":"2013","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2021.116000_b0110","doi-asserted-by":"crossref","first-page":"6735","DOI":"10.1016\/j.bmc.2011.09.045","article-title":"Small molecular CD4 mimics as HIV entry inhibitors","volume":"19","author":"Narumi","year":"2011","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2021.116000_b0115","doi-asserted-by":"crossref","first-page":"5663","DOI":"10.1073\/pnas.1112391109","article-title":"Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops","volume":"109","author":"Kwon","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmc.2021.116000_b0120","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1021\/acs.jmedchem.7b00179","article-title":"Synthesis, antiviral potency, in vitro ADMET and X-ray structure of potent CD4-mimics as entry inhibitors that target the Phe43 cavity of HIV-1 gp120","volume":"60","author":"Curreli","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2021.116000_b0125","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ejmech.2018.04.062","article-title":"Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120","volume":"154","author":"Curreli","year":"2018","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2021.116000_b0130","doi-asserted-by":"crossref","first-page":"10973","DOI":"10.1021\/bi061193r","article-title":"Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120","volume":"45","author":"Schon","year":"2006","journal-title":"Biochemistry"},{"key":"10.1016\/j.bmc.2021.116000_b0135","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1002\/cmdc.201800534","article-title":"Synthesis, antiviral activity, and structure-activity relationship of 1,3-benzodioxolyl pyrrole-based entry inhibitors targeting the Phe43 cavity in HIV-1 gp120","volume":"13","author":"Curreli","year":"2018","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmc.2021.116000_b0155","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1021\/acs.jmedchem.9b02149","article-title":"Preclinical optimization of gp120 entry antagonists as anti-HIV-1 agents with improved cytotoxicity and ADME properties through rational design, synthesis, and antiviral evaluation","volume":"63","author":"Curreli","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2021.116000_b0160","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1128\/JVI.80.2.835-844.2006","article-title":"Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant","volume":"80","author":"Wu","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.bmc.2021.116000_b0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002634","article-title":"Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies","volume":"8","author":"Abela","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.bmc.2021.116000_b0170","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.tim.2015.02.003","article-title":"HIV cell-to-cell transmission: effects on pathogenesis and antiretroviral therapy","volume":"23","author":"Agosto","year":"2015","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.bmc.2021.116000_b0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002634","article-title":"Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies","volume":"8","author":"Abela","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.bmc.2021.116000_b0180","doi-asserted-by":"crossref","first-page":"7484","DOI":"10.1128\/JVI.00230-12","article-title":"Neutralization resistance of virological synapse-mediated HIV-1 Infection is regulated by the gp41 cytoplasmic tail","volume":"86","author":"Durham","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.bmc.2021.116000_b0185","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02425-16","article-title":"Reduced potency and incomplete neutralization of broadly neutralizing antibodies against cell-to-cell transmission of HIV-1 with transmitted founder Envs","volume":"91","author":"Li","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.bmc.2021.116000_b0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003982","article-title":"Highly active antiretroviral therapies are effective against HIV-1 cell-to-cell transmission","volume":"10","author":"Agosto","year":"2014","journal-title":"PLoS.Pathog"},{"key":"10.1016\/j.bmc.2021.116000_b0195","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1128\/AAC.46.6.1896-1905.2002","article-title":"Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy","volume":"46","author":"Wei","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2021.116000_b0200","doi-asserted-by":"crossref","first-page":"7478","DOI":"10.1128\/jvi.71.10.7478-7487.1997","article-title":"Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype","volume":"71","author":"Bjorndal","year":"1997","journal-title":"J Virol"},{"key":"10.1016\/j.bmc.2021.116000_b0205","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1126\/science.6200935","article-title":"Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS","volume":"224","author":"Popovic","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.bmc.2021.116000_b0210","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1089\/08892220050058344","article-title":"Establishment of a CCR5-expressing T-lymphoblastoid cell line highly susceptible to R5 HIV type 1","volume":"16","author":"Baba","year":"2000","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.bmc.2021.116000_b0215","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1128\/JVI.73.10.8120-8126.1999","article-title":"Adaptation of a CCR5-using, primary human immunodeficiency virus type 1 isolate for CD4-independent replication","volume":"73","author":"Kolchinsky","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.bmc.2021.116000_b0220","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1128\/jvi.64.11.5270-5276.1990","article-title":"Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity","author":"Page","year":"1990","journal-title":"J Virol"},{"key":"10.1016\/j.bmc.2021.116000_b0225","doi-asserted-by":"crossref","first-page":"7783","DOI":"10.1128\/JVI.00673-09","article-title":"Cross-subtype neutralization sensitivity despite monoclonal antibody resistance among early subtype A, C, and D envelope variants of human immunodeficiency virus type 1","volume":"83","author":"Blish","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.bmc.2021.116000_b0230","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/088922202753747914","article-title":"HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus","volume":"18","author":"Long","year":"2002","journal-title":"AIDS Res Hum Retrov"},{"key":"10.1016\/j.bmc.2021.116000_b0235","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.virol.2008.12.032","article-title":"Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India","volume":"385","author":"Kulkarni","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.bmc.2021.116000_b0240","doi-asserted-by":"crossref","first-page":"10108","DOI":"10.1128\/JVI.79.16.10108-10125.2005","article-title":"Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies","volume":"79","author":"Li","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.bmc.2021.116000_b0245","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature01470","article-title":"Antibody neutralization and escape by HIV-1","volume":"422","author":"Wei","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2021.116000_b0250","doi-asserted-by":"crossref","first-page":"7552","DOI":"10.1073\/pnas.0802203105","article-title":"Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection","volume":"105","author":"Keele","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmc.2021.116000_b0255","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1126\/science.1093137","article-title":"Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission","volume":"303","author":"Derdeyn","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.bmc.2021.116000_b0260","doi-asserted-by":"crossref","first-page":"11776","DOI":"10.1128\/JVI.01730-06","article-title":"Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa","volume":"80","author":"Li","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.bmc.2021.116000_b0265","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1089\/088922203762688649","article-title":"Characterization and selection of HIV-1 subtype C isolates for use in vaccine development","volume":"19","author":"Williamson","year":"2003","journal-title":"AIDS Res Hum Retrov"},{"key":"10.1016\/j.bmc.2021.116000_b0270","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1006\/viro.1995.1016","article-title":"Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes","volume":"206","author":"Connor","year":"1995","journal-title":"Virol"},{"key":"10.1016\/j.bmc.2021.116000_b0275","doi-asserted-by":"crossref","first-page":"6705","DOI":"10.1128\/jvi.69.11.6705-6711.1995","article-title":"Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity","volume":"69","author":"He","year":"1995","journal-title":"J Virol"},{"key":"10.1016\/j.bmc.2021.116000_b0280","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1128\/jvi.59.2.284-291.1986","article-title":"Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone","volume":"59","author":"Adachi","year":"1986","journal-title":"J Virol"},{"key":"10.1016\/j.bmc.2021.116000_b0285","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1128\/JVI.72.2.986-993.1998","article-title":"Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides","volume":"72","author":"Rimsky","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.bmc.2021.116000_b0290","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.1128\/AAC.00648-12","article-title":"Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine","volume":"56","author":"Balamane","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2021.116000_b0295","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1128\/AAC.01345-09","article-title":"Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector","volume":"54","author":"Reuman","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2021.116000_b0300","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1128\/AAC.00614-13","article-title":"Prototypical recombinant multi-protease-inhibitor-resistant infectious molecular clones of human immunodeficiency virus type 1","volume":"57","author":"Varghese","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2021.116000_b0305","first-page":"391","article-title":"Antiviral activity of retrocyclin RC-101, a candidate microbicide against cell-associated HIV-1","volume":"29","author":"Gupta","year":"2013","journal-title":"AIDS Res"},{"key":"10.1016\/j.bmc.2021.116000_b0310","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1128\/AAC.01328-07","article-title":"Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides","volume":"52","author":"Lackman-Smith","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2021.116000_b0315","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1055\/s-0036-1588780","article-title":"Synthesis of 5-arylpyrrole-2-carboxylic acids as key intermediates for NBD series HIV-1 entry inhibitors","volume":"49","author":"Belov","year":"2017","journal-title":"Synthesis"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089621000080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089621000080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:11:49Z","timestamp":1760836309000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089621000080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":60,"alternative-id":["S0968089621000080"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2021.116000","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and antiviral activity of a series of CD4-mimetic small-molecule HIV-1 entry inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2021.116000","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116000"}}